Facioscapulohumeral Muscular Dystrophy clinical trials at UC Irvine
2 in progress, 1 open to eligible people
Showing trials for
Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (Reach)
open to eligible people ages 18-65
This is a study to evaluate the safety and efficacy of losmapimod in treating patients with Facioscapulohumeral Muscular Dystrophy (FSHD) over 48 weeks.
Irvine, California and other locations
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
Sorry, in progress, not accepting new patients
This study is an open-label extension to evaluate the safety and tolerability of long-term dosing of Losmapimod in patients with FSHD1 who participated in the ReDux4 study.
Irvine, California and other locations
Last updated: